PD-1 is induced on tumor-associated macrophages in obesity to directly restrain anti-tumor immunity
Jackie E. Bader(Vanderbilt University Medical Center), Jeffrey C. Rathmell(University of Chicago), Matthew Z. Madden(Emory University), Emily N. Arner(Vanderbilt University Medical Center), Emma S. Hathaway(Vanderbilt University Medical Center), Madelyn D. Landis(University of Pennsylvania), Bradley I. Reinfeld(Vanderbilt University Medical Center), Matthew A. Cottam(Vanderbilt University), KayLee K. Steiner(Vanderbilt University Medical Center), Kathryn E. Beckermann(Vanderbilt University Medical Center), Gabriel A. Needle(Vanderbilt University Medical Center), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alyssa H. Hasty(Vanderbilt University), Melissa M. Wolf(Vanderbilt University), Anthos Christofides(Beth Israel Deaconess Medical Center), Scott M. Haake(Vanderbilt University Medical Center), Xiang Ye(Qilu Hospital of Shandong University), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
|The Journal of Immunology|2011|2k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k